TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) shares crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $91.80 and traded as high as $92.99. TransMedics Group shares last traded at $92.21, with a volume of 564,162 shares trading hands.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on TMDX. Canaccord Genuity Group upped their target price on TransMedics Group from $95.00 to $120.00 and gave the company a "buy" rating in a research note on Friday, November 6th. JPMorgan Chase & Co. lifted their price target on shares of TransMedics Group from $73.00 to $85.00 and gave the stock a "neutral" rating in a research note on Friday, November 6th. Weiss Ratings upgraded shares of TransMedics Group from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, August 31st. Zacks Research raised shares of TransMedics Group from a "strong sell" rating to a "hold" rating in a report on Monday, November 2nd. Finally, Needham & Company LLC increased their price objective on shares of TransMedics Group from $106.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, November 6th. Five equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $113.30.
Get Our Latest Research Report on TransMedics Group
TransMedics Group Trading Up 0.9%
The company has a debt-to-equity ratio of 1.46, a current ratio of 4.53 and a quick ratio of 4.15. The business's 50 day simple moving average is $80.33 and its 200 day simple moving average is $91.80. The stock has a market cap of $3.20 billion, a P/E ratio of 24.99, a PEG ratio of 1.72 and a beta of 2.14.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.21. TransMedics Group had a return on equity of 13.30% and a net margin of 19.85%. The company had revenue of $203.01 million for the quarter, compared to analyst estimates of $178.06 million. During the same period in the prior year, the company posted $0.66 EPS. The company's revenue was up 41.1% compared to the same quarter last year. On average, analysts expect that TransMedics Group, Inc. will post 1.66 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, Director David Weill purchased 1,336 shares of the stock in a transaction on Friday, September 11th. The shares were purchased at an average cost of $81.63 per share, for a total transaction of $109,057.68. Following the completion of the transaction, the director directly owned 16,392 shares of the company's stock, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.90% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Barrow Hanley Mewhinney & Strauss LLC bought a new position in TransMedics Group in the 3rd quarter worth approximately $69,892,000. Braidwell LP lifted its holdings in TransMedics Group by 85.1% during the 2nd quarter. Braidwell LP now owns 609,715 shares of the company's stock worth $40,497,000 after buying an additional 280,324 shares in the last quarter. Deutsche Bank AG acquired a new position in TransMedics Group during the 2nd quarter worth $14,415,000. Bank of New York Mellon Corp bought a new position in TransMedics Group in the 2nd quarter valued at $12,869,000. Finally, Trek Financial LLC bought a new position in TransMedics Group in the 3rd quarter valued at $11,989,000. 99.67% of the stock is owned by institutional investors.
TransMedics Group Company Profile
(
Get Free Report)
TransMedics Group, Inc. is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services. The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TransMedics Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.
While TransMedics Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.